ANEBULO PHARMACEUTICALS INC (ANEB) Stock Price & Overview
NASDAQ:ANEB • US0345691036
Current stock price
The current stock price of ANEB is 0.36 USD. Today ANEB is down by -16.49%. In the past month the price decreased by -58.86%. In the past year, price decreased by -68.97%.
ANEB Key Statistics
- Market Cap
- 14.681M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.19
- Dividend Yield
- N/A
ANEB Stock Performance
ANEB Stock Chart
ANEB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ANEB. When comparing the yearly performance of all stocks, ANEB is a bad performer in the overall market: 98.6% of all stocks are doing better.
ANEB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANEB. ANEB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ANEB Earnings
ANEB Forecast & Estimates
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 2166.67% is expected in the next year compared to the current price of 0.36.
ANEB Groups
Sector & Classification
ANEB Financial Highlights
Over the last trailing twelve months ANEB reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 32.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.68% | ||
| ROE | -100.53% | ||
| Debt/Equity | 0 |
ANEB Ownership
ANEB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25 | 820.359B | ||
| JNJ | JOHNSON & JOHNSON | 17.96 | 542.756B | ||
| MRK | MERCK & CO. INC. | 21.61 | 272.255B | ||
| PFE | PFIZER INC | 8.86 | 152.391B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.2 | 117.972B | ||
| ZTS | ZOETIS INC | 16.49 | 49.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.59 | 28.645B | ||
| VTRS | VIATRIS INC | 5.94 | 17.245B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.05 | 11.031B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.586B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.117B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.111B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.91 | 4.916B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANEB
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Company Info
IPO: 2021-05-07
ANEBULO PHARMACEUTICALS INC
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107
Lakeway TEXAS US
CEO: Daniel Schneeberger
Employees: 2
Phone: 17372035270
ANEBULO PHARMACEUTICALS INC / ANEB FAQ
What does ANEBULO PHARMACEUTICALS INC do?
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Can you provide the latest stock price for ANEBULO PHARMACEUTICALS INC?
The current stock price of ANEB is 0.36 USD. The price decreased by -16.49% in the last trading session.
What is the dividend status of ANEBULO PHARMACEUTICALS INC?
ANEB does not pay a dividend.
What is the ChartMill rating of ANEBULO PHARMACEUTICALS INC stock?
ANEB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ANEBULO PHARMACEUTICALS INC?
ANEBULO PHARMACEUTICALS INC (ANEB) operates in the Health Care sector and the Pharmaceuticals industry.
When does ANEBULO PHARMACEUTICALS INC (ANEB) report earnings?
ANEBULO PHARMACEUTICALS INC (ANEB) will report earnings on 2026-05-11.